CGTLive’s Weekly Rewind – February 24, 2023

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Arsa-cel Shows Favorable Risk/Benefit Profile in up to 11 Years of Follow-up Data

Long term data from 2 clinical trials and expanded access programs were presented at WORLDSymposium 2023.

2. Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment

The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.

3. HSC Gene Therapy Demonstrates Improvements in Type 3 Gaucher Disease Case Study

The patient has not re-started any of his previous Gaucher-specific therapy since receiving AVR-RD-02.

4. Everett Meyer, MD, PhD, on Reducing GvHD in Leukemia Treatment

The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.

5. Graphite Bio Drops Lead Sickle Cell Gene-Edited Cell Therapy

The announcement of a “strategic realignment” comes less than 2 months after the company voluntarily paused the CEDAR clinical trial due to a serious, nula-cel-related adverse event.